MARKET

VTGN

VTGN

VistaGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8245
+0.0086
+1.05%
Opening 13:42 08/13 EDT
OPEN
0.8290
PREV CLOSE
0.8159
HIGH
0.8590
LOW
0.8000
VOLUME
1.83M
TURNOVER
--
52 WEEK HIGH
1.486
52 WEEK LOW
0.2943
MARKET CAP
59.16M
P/E (TTM)
-1.6256
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VTGN stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.

EPS

VTGN News

More
Week In Review: BioKangtai Acquires China Rights To AstraZeneca's COVID-19 Vaccine
Seeking Alpha - Article · 3d ago
EverInsight pays $5M upfront license payment to VistaGen
VistaGen Therapeutics (VTGN) receives $5M non-dilutive upfront license payment from EverInsight Therapeutics, the Company's partner for development and com
seekingalpha · 08/04 18:37
VistaGen Therapeutics Announces Receipt Of $5M Non-Dilutive Upfront License Payments From EverInsight Therapeutics For PH94B Strategic Collaboration
Benzinga · 08/04 12:07
Mid-Afternoon Market Update: Dow Surges 260 Points; Varian Medical Systems Shares Climb
Toward the end of trading Monday, the Dow traded up 0.98% to 26688.62 while the NASDAQ rose 1.62% to 10,919.64. The S&P also rose, gaining 0.91% to 3,300.92.
Benzinga · 08/03 18:35
Mid-Day Market Update: Crude Oil Rises 2%; ADT Shares Spike Higher
Midway through trading Monday, the Dow traded up 0.80% to 26638.57 while the NASDAQ rose 1.24% to 10879.04. The S&P also rose, gaining 0.70% to 3,294.14.
Benzinga · 08/03 16:06
VistaGen Therapeutics shares are trading lower after the company announced a proposed common stock offering of 15.6 million shares at $0.80 per share.
Benzinga · 08/03 10:36
VistaGen Therapeutics Prices 15.6M Share Underwritten Public Offering of Common Stock @$0.80/Share
VistaGen Therapeutics, Inc.(NASDAQ: VTGN) announced the pricing of its underwritten public offering of 15,625,000 shares of its common stock at a public offering price of $0.80 per share.
Benzinga · 08/03 09:49
7 Stocks To Watch For August 3, 2020
Some of the stocks that may grab investor focus today are:
Benzinga · 08/03 08:18

Industry

Pharmaceuticals
-1.85%
Pharmaceuticals & Medical Research
-1.12%

Hot Stocks

Symbol
Price
%Change

About VTGN

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.
More

Webull offers kinds of Vistagen Therapeutics Inc stock information, including NASDAQ:VTGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTGN stock methods without spending real money on the virtual paper trading platform.